Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Gregory Bailey
AddedFeb 13, 2024
UpdatedJun 28, 2026
Gregory Bailey

Gregory Bailey

Board Member, AgeX Therapeutics

CrunchbaseThe Org

Gregory Bailey's Career

AgeX Therapeutics
AgeX Therapeutics

Alameda, CA, US

Board Member· Board
Sentien Biotechnologies
Sentien Biotechnologies

Lexington, MA, US

Board Member· Board
Juvenescence
Juvenescence

Mobile, AL, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Gregory Bailey's Career

AgeX Therapeutics
AgeX Therapeutics

Alameda, CA, US

Board Member· Board
Sentien Biotechnologies
Sentien Biotechnologies
Series A$15.1M42008Lexington, MA, US
Board Member· Board

Leadership at Sentien Biotechnologies

Rich GanzRich GanzBoard Member
Giacomo ChiesiGiacomo ChiesiBoard Member
Martin HeideckerMartin HeideckerBoard Member
Johannes FruehaufJohannes FruehaufBoard Member
Brian MillerBrian MillerBoard Member
Biju ParekkadanBiju ParekkadanBoard Member
Juvenescence
Juvenescence
Series C$219.2M412016Mobile, AL, US
Co-Founder

Leadership at Juvenescence

Declan DooganDeclan DooganCo-Founder
Anthony Chow, CFAAnthony Chow, CFACo-Founder
Alexander PickettAlexander PickettCo-Founder
Jim MellonJim MellonCo-Founder
Richard MarshallRichard MarshallCEO

Similar to Juvenescence

Rejuveron Life SciencesRejuveron Life SciencesSchlieren, Zürich, CHDrug Development, Therapiesest. 2019Rejuveron Life SciencesSchlieren, Zürich, CH · est. 2019

Rejuveron Life Sciences: A biotech platform investing in innovative therapies for healthy aging.

Late Stage Private · $97.6M22
LongeveronLongeveronMiami, FL, USCellular Therapiesest. 2014LongeveronMiami, FL, US · est. 2014

Longeveron Inc., a clinical-stage biotech firm, develops cellular therapies for aging-related and life-threatening conditions globally.

Public · $15.4M11
Juventas TherapeuticsJuventas TherapeuticsCleveland, OH, USRegenerative Therapiesest. 2007Juventas TherapeuticsCleveland, OH, US · est. 2007

Juventas Therapeutics: A clinical-stage biotech firm innovating regenerative therapies for critical diseases.

Series B · $48.7M11
Rejuvenation Technologies Inc.Rejuvenation Technologies Inc.Mountain View, CA, USTherapiesest. 2016Rejuvenation Technologies Inc.Mountain View, CA, US · est. 2016

Biotech firm advancing telomere-lengthening therapies for aging reversal.

Series B · $15.3M18

Gregory Bailey's Co-Investors

Andrew BanksAndrew BanksCo-invested · Juvenescence SeedKarim HakimzadehKarim HakimzadehCo-invested · Juvenescence SeedJohn W. ChildsJohn W. ChildsCo-invested · Bristol Myers Squibb Post Ipo EquityCarl IcahnCarl IcahnCo-invested · Bristol Myers Squibb Post Ipo EquityKingsley AdvaniKingsley AdvaniCo-invested · Juvenescence Series B

Gregory Bailey's Similar Executives & Operators

Soemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance Retail

People Similar to Gregory Bailey

Daniel HendersonDaniel HendersonCo-Founder · PaxVaxRaphael NirRaphael NirCo-Founder · Vuja De SciencesJuan EnriquezJuan EnriquezFounder & CEO · BiotechonomyKevin AppelbaumKevin AppelbaumCo-Founder · Better TherapeuticsDon HardisonDon HardisonBoard Member · HTG Molecular Diagnostics